Kamoa-Kakula Monthly Progress Update Expected on June 2

Kolwezi, Democratic Republic of Congo--(Newsfile Corp. - June 1, 2021) - Ivanhoe Mines (TSX: IVN) (OTCQX: IVPAF) announced today that the May progress update for the Kamoa-Kakula Copper Project in the Democratic Republic of Congo (DRC) is expected to be issued on June 2, 2021.

The Kamoa-Kakula Phase 1 concentrator plant produced its first copper concentrate on May 25^th and the plant is in the process of hot commissioning and ramp up.

About Ivanhoe Mines

Ivanhoe Mines is a Canadian mining company focused on advancing its three principal joint-venture projects in Southern Africa: the development of major new, mechanized, underground mines at the Kamoa-Kakula copper discoveries in the Democratic Republic of Congo and at the Platreef palladium-rhodium-platinum-nickel-copper-gold discovery in South Africa; and the extensive redevelopment and upgrading of the historic Kipushi zinc-copper-germanium-silver mine, also in the Democratic Republic of Congo .

Kamoa-Kakula began producing copper concentrates in May 2021 and, through phased expansions, is positioned to become one of the world's largest copper producers. Kamoa-Kakula and Kipushi will be powered by clean, renewable hydro-generated electricity and will be among the world's lowest greenhouse gas emitters per unit of metal produced. Ivanhoe Mines has pledged to achieve net-zero operational greenhouse gas emissions (Scope 1 and 2) at the Kamoa-Kakula Copper Mine when large-scale electric, hydrogen and hybrid underground mining equipment become commercially available. Ivanhoe also is exploring for new copper discoveries on its wholly-owned Western Foreland exploration licences in the Democratic Republic of Congo, near the Kamoa-Kakula Project.

Information Contacts

Investors:
Bill Trenaman
+1.604.331.9834

Media:
Matthew Keevil
+1.604.558.1034

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/86038

You May Also Be Interested In

• Copel Achieves 20.8% Increase in Recurring EBITDA in 2Q26 Recurring
• AI-empowered Pipeline-in-a-drug Option: Insilico Medicine Nominates ISM9077, Potential First-in-class Target Y Inhibitor, as Preclinical Candidate (PCC) for Ocular Diseases, Inflammatory Disorders and
• April Iannazzone Expands Seller-Financed Home Options via PropertIQ Homes